BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Tagami K, Kashiwase Y, Yokoyama A, Nishimura H, Miyano K, Suzuki M, Shiraishi S, Matoba M, Ohe Y, Uezono Y. The atypical antipsychotic, olanzapine, potentiates ghrelin-induced receptor signaling: An in vitro study with cells expressing cloned human growth hormone secretagogue receptor. Neuropeptides 2016;58:93-101. [DOI: 10.1016/j.npep.2015.12.010] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 2.7] [Reference Citation Analysis]
Number Citing Articles
1 Davis MP, Sanger GJ. The Benefits of Olanzapine in Palliating Symptoms. Curr Treat Options Oncol 2020;22:5. [PMID: 33244634 DOI: 10.1007/s11864-020-00804-1] [Reference Citation Analysis]
2 Malekzadeh S, Heidari MR, Razavi BM, Rameshrad M, Hosseinzadeh H. Effect of safranal, a constituent of saffron, on olanzapine (an atypical antipsychotic) induced metabolic disorders in rat. Iran J Basic Med Sci 2019;22:1476-82. [PMID: 32133067 DOI: 10.22038/IJBMS.2019.13992] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
3 Wu TH, Chiu CC, Goh KK, Chen PY, Huang MC, Chen CH, Lu ML. Relationship between metabolic syndrome and acylated/desacylated ghrelin ratio in patients with schizophrenia under olanzapine medication.J Psychopharmacol. 2020;34:86-92. [PMID: 31692408 DOI: 10.1177/0269881119885260] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
4 Tunçel ÖK, Sarısoy G, Bilgici B, Pazvantoğlu O, Çetin E, Tunçel EK. Adipocytokines and ghrelin level of bipolar patients from manic episode to euthymic episode. Nord J Psychiatry 2018;72:150-6. [PMID: 29132244 DOI: 10.1080/08039488.2017.1402953] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
5 Singh R, Bansal Y, Sodhi RK, Saroj P, Medhi B, Kuhad A. Modeling of antipsychotic-induced metabolic alterations in mice: An experimental approach precluding psychosis as a predisposing factor. Toxicology and Applied Pharmacology 2019;378:114643. [DOI: 10.1016/j.taap.2019.114643] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
6 Rice J, Ramtekkar U. Integrative Management of Metabolic Syndrome in Youth Prescribed Second-Generation Antipsychotics. Med Sci (Basel) 2020;8:E34. [PMID: 32824428 DOI: 10.3390/medsci8030034] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
7 Reynolds GP, McGowan OO. Mechanisms underlying metabolic disturbances associated with psychosis and antipsychotic drug treatment. J Psychopharmacol 2017;31:1430-6. [PMID: 28892404 DOI: 10.1177/0269881117722987] [Cited by in Crossref: 30] [Cited by in F6Publishing: 22] [Article Influence: 6.0] [Reference Citation Analysis]
8 Doijen J, Van Loy T, Landuyt B, Luyten W, Schols D, Schoofs L. Advantages and shortcomings of cell-based electrical impedance measurements as a GPCR drug discovery tool. Biosens Bioelectron. 2019;137:33-44. [PMID: 31077988 DOI: 10.1016/j.bios.2019.04.041] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
9 Freyberg Z, Aslanoglou D, Shah R, Ballon JS. Intrinsic and Antipsychotic Drug-Induced Metabolic Dysfunction in Schizophrenia. Front Neurosci 2017;11:432. [PMID: 28804444 DOI: 10.3389/fnins.2017.00432] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 5.8] [Reference Citation Analysis]
10 Raue S, Wedekind D, Wiltfang J, Schmidt U. The Role of Proopiomelanocortin and α-Melanocyte-Stimulating Hormone in the Metabolic Syndrome in Psychiatric Disorders: A Narrative Mini-Review. Front Psychiatry 2019;10:834. [PMID: 31798479 DOI: 10.3389/fpsyt.2019.00834] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
11 He M, Qian K, Zhang Y, Huang XF, Deng C, Zhang B, Gao G, Li J, Xie H, Sun T. Olanzapine-Induced Activation of Hypothalamic Astrocytes and Toll-Like Receptor-4 Signaling via Endoplasmic Reticulum Stress Were Related to Olanzapine-Induced Weight Gain. Front Neurosci 2020;14:589650. [PMID: 33584172 DOI: 10.3389/fnins.2020.589650] [Reference Citation Analysis]
12 Luo C, Liu J, Wang X, Mao X, Zhou H, Liu Z. Pharmacogenetic Correlates of Antipsychotic-Induced Weight Gain in the Chinese Population. Neurosci Bull 2019;35:561-80. [PMID: 30607769 DOI: 10.1007/s12264-018-0323-6] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 3.7] [Reference Citation Analysis]
13 Horska K, Kotolova H, Karpisek M, Babinska Z, Hammer T, Prochazka J, Stark T, Micale V, Ruda-Kucerova J. Metabolic profile of methylazoxymethanol model of schizophrenia in rats and effects of three antipsychotics in long-acting formulation. Toxicol Appl Pharmacol 2020;406:115214. [PMID: 32866524 DOI: 10.1016/j.taap.2020.115214] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
14 He M, Huang X, Gao G, Zhou T, Li W, Hu J, Chen J, Li J, Sun T. Olanzapine-induced endoplasmic reticulum stress and inflammation in the hypothalamus were inhibited by an ER stress inhibitor 4-phenylbutyrate. Psychoneuroendocrinology 2019;104:286-99. [DOI: 10.1016/j.psyneuen.2019.03.017] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
15 Xu H, Zhuang X. Atypical antipsychotics-induced metabolic syndrome and nonalcoholic fatty liver disease: a critical review. Neuropsychiatr Dis Treat 2019;15:2087-99. [PMID: 31413575 DOI: 10.2147/NDT.S208061] [Cited by in Crossref: 20] [Cited by in F6Publishing: 10] [Article Influence: 6.7] [Reference Citation Analysis]
16 Smith KR, Moran TH. Gastrointestinal peptides in eating-related disorders. Physiol Behav 2021;238:113456. [PMID: 33989649 DOI: 10.1016/j.physbeh.2021.113456] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
17 Kawazoe H, Uozumi R, Murakami A, Yamashita M, Kobayashi-Taguchi K, Kusakabe E, Yamasawa H, Yakushijin Y, Nakamura T, Kamei Y. Olanzapine plus aprepitant, palonosetron, and dexamethasone for nausea and vomiting in patients with breast cancer receiving anthracycline: A retrospective study. Sci Rep 2018;8:16232. [PMID: 30389996 DOI: 10.1038/s41598-018-34618-x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]